Navigation Links
Study of successful drug targets could hasten development of new medications
Date:1/31/2008

Guidance from an innovative computational approach could speed up the process and cut down the cost of new drug development, researchers from the University of Chicago Medical Center and Columbia University suggest in a study to be published in the February 2008 issue of Genome Research, available early online.

The researchers analyzed specific properties of the human genes and proteins that serve as targets for nearly a thousand FDA-approved drugs. They identified a number of characteristics that were common among successful drug targetsand especially common among high-revenue drugs.

"To make a good drug, you need to find a good drug target," said Andrey Rzhetsky, PhD, professor of medicine at the University of Chicago and senior author of the study. "Here we provide guidelines for more efficient target screening. When a drug company must decide which target to pursue among pathologic pathways, this could provide useful estimates of each target's expected success rate."

Gleevec, Prozac, Viagra: these successful drugs all target specific proteins and provoke a desired response. They reward the people who need them, as well as to those who invent, manufacture and market them.

But he development of a new drug is complicated and expensive, "a fusion of art and science," the authors note. It involves finding an accessible drug target and a molecule that binds that target as selectively as possible. Then it must trigger a desirable physiological change.

But "every highly visible success," the authors note, "rests on an iceberg of invisible failures." Since the estimated cost of developing a new drug ranges from $800 million to $1.2 billion, "information that helps only a little bit," Rzhetsky said, "can still be quite valuable."

What characteristics, they asked, distinguished the targets that eventually became the focus of such successful drugs" How are these genes or proteins different from the tens of thousa
'/>"/>

Contact: John Easton
John.Easton@uchospitals.edu
772-702-6241
University of Chicago Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Conservation strategies must shift with global environmental change, says CU-Boulder study
2. Virginia Tech plant scientist leads study on genomics of parasitic plants
3. Smithsonian study: Sediment prediction tools off the mark
4. Prison study to investigate link between diet and behavior
5. Queens study connects obesity with nervous system
6. LSU, Yale team study agricultural impact on Mississippi River
7. Diet and lifestyle critical to recovery, says study
8. Scientists study the link between childrens nutrition and adult diseases
9. New Argonne study may shed light on protein-drug interactions
10. Sea otter study reveals striking variability in diets and feeding strategies
11. Study: weight-loss tips differ in African-American, mainstream magazines

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ON ROUGE Antarctica has long held secrets of the ...l recently, there has been very little information... miles of ice for millions of years. Now, a team o...U have been funded to the tune of $10 million dol...o get to the bottom of things literally. These sc...
(Date:11/23/2009)...ngton, D.C. The community-associated strain of th...a resistant to most common antibioticsposes a far ... making its way into hospitals, according to a stu...iseases . , The new threat is easily picked up ...es and has increased the overall burden of MRSA wi...
(Date:11/23/2009)...ngton, CT Current research suggests that a common... The related report by Nichols et al, "Unique Lip...Class of TLR2 Ligands Capable of Enhancing Autoimm... American Journal of Pathology . , Multiple scle...cks the brain and spinal cord, affects nearly 1 in...
Breaking Biology News(10 mins):LSU gets to the bottom of things -- in Antarctica 2New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2Cambrex Continuous Flow Microwave Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award 5599 1Cambrex Continuous Flow Microwave Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award 5599 2Babies Injured in Car Seats Used Outside of Cars 59817 1Babies Injured in Car Seats Used Outside of Cars 59817 2Babies Injured in Car Seats Used Outside of Cars 59817 3School Meals Need to Get Healthier 3A Report 59815 1School Meals Need to Get Healthier 3A Report 59815 2School Meals Need to Get Healthier 3A Report 59815 3School Meals Need to Get Healthier 3A Report 59815 4
...nced the winners of its student travel award to at...and the International Biophysics Congress in Long ...nts of this competitive award are selected based o...ho will present a paper at the conference. Each a...zed at a reception on Saturday, February 2, 2008. ...
...diopathic pulmonary fibrosis is a disease with unk...cted, it is already in an advanced stage. Patients...ulmonary gas exchange, and have a very reduced qua...tment, they rarely survive 5 years after being dia...ut of 100,000 men and 7 out of 100,000 women, norm...
...unds could make sutures a relic of medical history...laced on a surgical wound and exposed to an infrar... it and the tissue, thus perfectly sealing the wou... is extracted from crab shells and has Food and Dr...t results indicate that it has strongest potential...
Other Biology News:Biophysical Society announces winners of 2008 Student Travel Awards 2Biophysical Society announces winners of 2008 Student Travel Awards 3Biophysical Society announces winners of 2008 Student Travel Awards 4Biophysical Society announces winners of 2008 Student Travel Awards 5Translational research patented first experimental treatment against idiopathic pulmonary fibrosis 2Surgery without stitches 2
(Date:11/23/2009)... communication, computation and more powerful ways...se quantum states as carriers of information is an...ave shown, mathematically, how to gently tease out...eping the information intact. Their work is report...s and highlighted with a Viewpoint in Physics (...
(Date:11/23/2009)...wswire-FirstCall/--PDLBioPharma,Inc.(PDL)(Nasdaq: ...er27,2009astheex-dividenddateforits$200millionspec...ationtransactioncompletedonNovember2,2009.Thedivid...ecordontherecorddate,December1,2009.NASDAQhassetth...hareofcommonstockforpurposesoftheex-dividenddateon...
(Date:11/23/2009)...-FirstCall/--NeogenCorporation(Nasdaq: NEOG )annou...ogen,sBoardofDirectorsatthecompany,srecentannualme...rsofexperienceinthefood,agriculture,andtradeindust...lturaleconomicsatVirginiaTechUniversity.FromJanuar...ulturenegotiatorwiththerankofambassador. ,, "Si...
(Date:11/23/2009)...uneDesignC or p.(IDC)announcedtodaythatDr.BruceL.A...sasuccessfultrackrec or dinbiotechnologyexecutivem...ymoGenetics,inSeattle,WAandChiefScientificOfficera...ttp://www.newscom.com/cgi-bin/prnh/20091123/SF1522...iveOfficercommented,"IamdelightedtowelcomeDr.Bruce...
Breaking Biology Technology:PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2Richard T. Crowder Joins Neogen's Board of Directors 2Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2
...ocus on Late-Stage and Marketed ...nd OXFORD, England, May 1 ,EUSA Pharma Inc (,EUSA,...y,focused on oncology, pain control and critical c...clonal antibody research business to the French,co...rently, EUSA has,divested its recombinant L-aspara...
...sdaq:,VICL) today announced that the company will ...ch 31, 2008, before the opening of trading on,Thur...cast to discuss the,financial results and provide ... May 8. The call is open on a listen-only basis to...details on independent and partnered,development p...
...:,FVRL), a biopharmaceutical company developing pa...atment of cancer, announced today that it will,hos...Eastern Time on,Thursday, May 8, 2008 to discuss t... A press release will be issued after the U.S. sto...wscom.com/cgi-bin/prnh/20080404/LAF521LOGO ), A l...
Other Biology Technology:EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product 2EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product 3Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results 2Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008 2
Rat Anti-Mouse Endoglin Monoclonal Antibody, Fluorescein Conjugated, Clone 209701 from R&D Systems
Goat Anti-Rat CNTF R alpha Polyclonal Antibody, Unconjugated from R&D Systems
Rat Anti-Human MFRP Monoclonal Antibody, Unconjugated, Clone 291218 from R&D Systems
Goat Anti-Human RELT / TNFRSF19L Polyclonal Antibody, Unconjugated from R&D Systems
Biology Products: